Pilot study of the effect of terodiline chloride (Bicor) in obstructive pulmonary disease.
Terodiline chloride, 150 mg daily, was administered to 10 patients with obstructive pulmonary disease, and pulmonary function tests were performed before and during two weeks of therapy. Serious side effects of anticholinergic type developed in two patients who stopped treatment. Two patients were excluded from the trial for other reasons. The remaining six patients showed signs of bronchodilation. Owing to the high incidence of side effects, treatment with more than 75 mg terodiline chloride per day is impracticable.
D000328:Adult; D000368:Aged; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002082:Butylamines / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D005541:Forced Expiratory Volume; D006339:Heart Rate; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014797:Vital Capacity
D001993:Bronchodilator Agents; D002082:Butylamines